Medimmune Limited

Abbott Laboratories Corporation

The Brigham and Women's Hospital, Inc.

Yihong Yao

Partha S Chowdhury

Meina Liang

Reena Varkey

Koustubh Ranade

Yen-Wah Lee

Katie Streicher

Ethan Grant

Lydia Greenlees

Melissa Parker

Anthony Coyle

Susan E Brophy

Bing Wang

Michael A Bowen

Brandon Higgs

Lorin Roskos

Barbara E White

Bruce J Dille

Steven A Greenberg

Gianluca Carlesso

Chris Morehouse

Gerard Davis

Nicolette Jeanblanc

Linda Chang

Bahija Jallal

Jiaqi Huang

Theresa Lavalle

Wei Zhu

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of using antibodies to determine periostin levels in a sample

Monoclonal antibodies which bind human periostin

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Without limitation, this disclosure relates to compositions and methods for detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin receptor isoform B (IR-B) in a tissue sample. The disclosure also relates to methods of diagnosis and classification based at least in part upon detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin B (IR-B) in a tissue sample. Methods of treating a subject based upon such a classification are among additional aspects of the disclosure presented herein.

Quantification of IR-A and IR-B for tumor classification

Growing community of inventors

Gaithersburg, MD, United States of America

Yihong Yao